KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Income (2016 - 2025)

Historic Operating Income for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $3.3 billion.

  • Gilead Sciences' Operating Income rose 27466.22% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 billion, marking a year-over-year increase of 117615.57%. This contributed to the annual value of $1.7 billion for FY2024, which is 7814.6% down from last year.
  • Per Gilead Sciences' latest filing, its Operating Income stood at $3.3 billion for Q3 2025, which was up 27466.22% from $2.5 billion recorded in Q2 2025.
  • Gilead Sciences' 5-year Operating Income high stood at $3.8 billion for Q3 2021, and its period low was -$4.3 billion during Q1 2024.
  • Moreover, its 5-year median value for Operating Income was $2.2 billion (2021), whereas its average is $1.8 billion.
  • In the last 5 years, Gilead Sciences' Operating Income soared by 76548.22% in 2023 and then tumbled by 35348.97% in 2024.
  • Over the past 5 years, Gilead Sciences' Operating Income (Quarter) stood at $940.0 million in 2021, then soared by 141.17% to $2.3 billion in 2022, then dropped by 28.89% to $1.6 billion in 2023, then surged by 52.11% to $2.5 billion in 2024, then skyrocketed by 35.69% to $3.3 billion in 2025.
  • Its Operating Income stands at $3.3 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.2 billion for Q1 2025.